Crossmark

Remarkable response to chidamide plus rituximab in an elderly patient with recurrent, chemotherapy-refractory diffuse larger B-cell lymphoma carrying CREBBP mutation

Crossref DOI link: https://doi.org/10.1007/s00277-023-05183-9

Published Online: 2023-03-29

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Dongdong https://orcid.org/0000-0003-4362-8984
Han, Yidi

Dong, Youhong
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82200214)

Key Research and Development Project of Hubei (2022BCE028)

Youth and Middle-aged Scientific and Technological Innovation Leading Talents Program of the Corps (Q20222101)

Platform Special Fund for Scientific Research of Xiangyang No.1 People’s Hospital (XYY2022P05)

Instructional projects of Hubei Provincial Health and Health Commission (WJ2023F074)
License Information

Text and Data Mining valid from 2023-03-29

Version of Record valid from 2023-03-29
More Information

Article History

Received: 6 February 2023

Accepted: 14 March 2023

First Online: 29 March 2023

Declarations

:

: This study was approved by the Ethics and Scientific Committee of Hubei University of Medicine (XYY2021002) and was performed according to the Good Clinical Practice Guidelines and the Helsinki Declaration.

: An informed consent was received from patients authorized representative for publication of identifying information/images in an online open-access publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below